Sec Form 4 Filing - Paolini John F. @ Kiniksa Pharmaceuticals, Ltd. - 2020-02-19

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Paolini John F. 2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [ KNSA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP & Chief Medical Officer (Last) (First) (Middle) C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE 2 CHURCH STREET 3. Date of Earliest Transaction (MM/DD/YY) 02/19/2020 (Street) HAMILTON, D0HM11 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A Common Shares 02/19/2020 M( 1 ) 22,477 A $ 3.8 40,477 D Class A Common Shares 02/19/2020 S( 1 ) 22,477 D $ 18.27 ( 2 ) 18,000 D Class A Common Shares 02/20/2020 M( 1 ) 9,803 A $ 3.8 27,803 D Class A Common Shares 02/20/2020 S( 1 ) 8,687 D $ 18.91 ( 3 ) 19,116 D Class A Common Shares 02/20/2020 S( 1 ) 1,116 D $ 19.32 ( 4 ) 18,000 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Share Option $ 3.8 02/19/2020 M( 1 ) 22,477 ( 5 ) 06/28/2027 Class A Common Shares 22,477 $ 0 76,345 D Share Option $ 3.8 02/20/2020 M( 1 ) 9,803 ( 5 ) 06/28/2027 Class A Common Shares 9,803 $ 0 66,542 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Paolini John F. C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET HAMILTON, D0HM11 SVP & Chief Medical Officer Signatures /s/ John F. Paolini 02/21/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. ( 2 )This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.26 to $18.36. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. ( 3 )This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.30 to $19.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. ( 4 )This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.31 to $19.37. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. ( 5 )The Share Option granted the reporting person an option to purchase 110,138 Shares. 25% of such Shares vested and became exercisable on June 28, 2018, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.